Internal Reference Number: FOI_7622
Date Request Received: 18/12/2023 00:00:00
Date Request Replied To: 19/01/2024 00:00:00
This response was sent via: By Email
Request Summary: Treatment of dermatological conditions
Request Category: Companies
| Question Number 1: How many patients were treated in the last 4 months (August to November 2023) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib | |
| Answer To Question 1: • Abrocitinib - 0 • Acitretin - 30 • Alitretinoin - <5 • Azathioprine - <5 • Baricitinib - <5 • Ciclosporin - 11 • Dupilumab - 22 • Methotrexate - 33 • Mycophenolate mofetil - 0 • Pimecrolimus - 0 • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only - 7 • Tacrolimus ointment - 23 • Tralokinumab - 0 • Upadacitinib - 6 | |
| Question Number 2: Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 2: All patients in Q1 were aged 18+ except <5 were aged 6-11 for Tacrolimus ointment treatment; <5 were aged 6-11 for Phototherapy (UVB or PUVA) for Atopic Dermatitis only; and <5 were aged 12-17 for Phototherapy (UVB or PUVA) for Atopic Dermatitis only. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
